Crescent Biopharma Stock Price, News & Analysis
Company Description
Crescent Biopharma (NASDAQ: cbio) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $461.6M, ranking #3,419 among all listed U.S. companies by market cap.
cbio stock has gained 16.3% over the past year. Shares last traded at $16.62.
On a trailing twelve-month basis, Crescent Biopharma reported revenue of $10.8M with net income of -$153.9M. The company operates at a net profit margin of -1419.6%.
This page provides a comprehensive overview of cbio stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Crescent Biopharma (cbio) stock last traded at $16.62, up 9.51% from the previous close. Over the past 12 months, the stock has gained 16.3%. At a market capitalization of $461.6M, cbio is classified as a small-cap stock with approximately 27.6M shares outstanding.
Latest News
Crescent Biopharma has 10 recent news articles, with the latest published 4 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, clinical trial. View all cbio news →
SEC Filings
Crescent Biopharma has filed 5 recent SEC filings, including 2 Form 424B3, 1 Form POS AM, 1 Form 8-K, 1 Form 10-K. The most recent filing was submitted on March 17, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all cbio SEC filings →
Financial Highlights
Crescent Biopharma generated $10.8M in revenue over the trailing twelve months, operating income reached -$152.6M (-1407.5% operating margin), and net income was -$153.9M, reflecting a -1419.6% net profit margin. The company generated -$71.5M in operating cash flow. With a current ratio of 6.56, the balance sheet reflects a strong liquidity position.
Upcoming Events
CR-002 IND submission
CR-002 IND planned
CR-002 IND submission
CR-001 proof-of-concept data
CR-001 clinical data
Proof-of-concept data readout
ASCEND proof-of-concept data
CR-001 PoC data
CR-003 PoC data
Crescent Biopharma has 22 upcoming scheduled events. The next event, "CR-002 IND submission", is scheduled for May 1, 2026 (in 30 days). 9 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the cbio stock price.
Short Interest History
Short interest in Crescent Biopharma (cbio) currently stands at 1.1 million shares, up 24.2% from the previous reporting period, representing 4.4% of the float. Over the past 12 months, short interest has increased by 3185.3%. This relatively low short interest suggests limited bearish sentiment. The 5.4 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for Crescent Biopharma (cbio) currently stands at 5.4 days, down 29.5% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 443% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 11.6 days.
cbio Company Profile & Sector Positioning
Crescent Biopharma (cbio) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing cbio often look at related companies in the same sector, including NeOnc Technologies Holdings Inc (NTHI), Kyverna Therapeutics (KYTX), Nuvectis Pharma, Inc. (NVCT), Innate Pharma Sa (IPHA), and Caribou Biosciences, Inc. (CRBU). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate cbio's relative position within its industry.